Overview
Professor Angus Dalgleish discusses the role of low dose naltrexone (LDN) in cancer treatment, focusing on its immune-modulating and anti-cancer properties, supported by case studies and mechanistic insights.
LDN’s Mechanism of Action in Cancer
- LDN is bioactive and demonstrates both direct anti-cancer properties and indirect immune system re-education.
- Research indicates that low doses of naltrexone can inhibit tumor growth.
- LDN may exert anticancer effects by acting on receptors beyond opioid receptors, especially toll-like receptors (TLRs).
Clinical Observations and Case Studies
- Early clinical observations involved cancer patients (including stage four melanoma and metastatic breast cancer) responding better than expected while on LDN.
- A notable case involved a woman with melanoma and Crohn’s disease, where LDN enabled reduction of immunosuppressive treatments and stabilized her cancer.
- LDN enabled rapid improvement in inflammatory conditions, leading to better cancer outcomes.
Immune Modulation and TLRs
- LDN is observed to correct immune imbalances and modulate the immune response.
- TLRs (specifically TLR 7, 8, and 9) are impacted by LDN, which may explain its benefits in autoimmunity and cancer.
- Overactive TLR signaling is linked to diseases like Crohn’s, inflammatory disorders, and certain cancers.
Laboratory and Clinical Evidence
- Studies show LDN affects cancer cell lines directly (in-vitro) and indirectly through inflammation regulation.
- LDN helps activate and restore normal immune function in cancer patients.
- Evidence suggests LDN’s lower doses target TLRs, while higher doses primarily affect opioid receptors.
Combination Therapies
- The use of cannabinoids alongside LDN is highlighted as a promising direction for cancer treatment.
Recommendations / Advice
- Consider LDN as an adjunct therapy for cancer, especially in cases with immune dysregulation or inflammatory disorders.
- Monitor immune function and adjust immunosuppressive therapies accordingly when using LDN.